kymera
therapeutics
deliver
two
podium
presentations
annual
targeted
protein
degradation
summit
watertown
globe
newswire
kymera
therapeutics
nasdaq
kymr
biopharmaceutical
company
advancing
targeted
protein
degradation
tpd
deliver
novel
small
molecule
protein
degrader
therapeutics
share
two
key
presentations
annual
targeted
protein
degradation
summit
kymera
president
ceo
nello
mainolfi
phd
deliver
keynote
presentation
targeted
protein
degradation
beyond
oncology
share
recent
data
related
company
program
including
findings
company
trial
hidradenitis
suppurativa
hs
patients
haojing
rong
phd
vice
president
development
present
kymera
efforts
elucidate
preclinical
pharmacokinetic
pharmacodynamic
relationships
predict
clinical
pk
pd
targeted
protein
degradation
beyond
oncology
keynote
plenary
session
presented
mainolfi
phd
president
chief
executive
officer
kymera
et
mainolfi
present
company
pegasus
platform
approach
target
selection
focusing
degrader
program
immunology
inflammation
present
interim
findings
trial
evaluating
expression
activity
kymera
lead
protein
degrader
hidradenitis
suppurativa
hs
atopic
dermatitis
ad
research
trial
evaluating
expression
degrader
activity
hs
ad
patients
kymera
continued
demonstrate
potential
degraders
treat
range
diseases
beyond
oncology
look
forward
sharing
findings
approach
colleagues
broadly
highlight
importance
understanding
pkpd
across
different
cell
types
responsible
inflammatory
said
mainolfi
phd
president
chief
executive
officer
kymera
data
first
shared
poster
presentation
annual
symposium
hidradenitis
suppurativa
advances
shsa
october
key
findings
presented
demonstrated
levels
higher
diseased
compared
unaffected
skin
supporting
relevance
signaling
pathway
hs
study
also
showed
ex
vivo
incubation
hs
blood
kymera
protein
degrader
reduced
level
approaching
lower
limits
detection
across
pbmc
subsets
pk
pd
relationship
targeted
protein
degradation
tpd
virtual
poster
presentation
presented
rong
phd
vice
president
development
pm
et
kymera
second
presentation
center
critical
need
understand
key
principles
pk
pd
relationships
preclinical
species
new
modality
use
learnings
establish
optimal
dosing
paradigms
schedules
preclinical
species
eventually
predict
human
pk
pd
active
doses
accurately
possible
quantitative
system
pharmacology
modeling
essential
tool
dissect
pk
pd
interplay
vivo
predict
dosing
humans
said
rong
phd
vice
president
preclinical
development
kymera
kymera
view
preclinical
investigation
pkpd
relationships
across
cell
tissue
types
opportunity
glean
essential
information
guide
step
drug
development
kymera
therapeutics
kymera
therapeutics
biopharmaceutical
company
focused
transformative
new
approach
address
previously
intractable
disease
targets
kymera
advancing
field
targeted
protein
degradation
accessing
body
innate
protein
recycling
machinery
degrade
dysregulated
proteins
kymera
pegasus
targeted
protein
degradation
platform
harnesses
body
natural
protein
recycling
machinery
degrade
proteins
focus
nodes
validated
pathways
currently
inaccessible
conventional
therapeutics
kymera
accelerating
drug
discovery
unmatched
ability
target
degrade
intractable
proteins
advance
new
treatment
options
patients
kymera
initial
programs
target
irakimid
within
tlr
jak
stat
pathways
providing
opportunity
treat
broad
range
diseases
hematologic
malignancies
solid
tumors
information
visit
kymera
therapeutics
proprietary
protein
degradation
platform
created
team
experienced
drug
hunters
improve
effectiveness
targeted
protein
degradation
generate
pipeline
novel
therapeutics
previously
undruggable
diseases
platform
consists
informatics
driven
target
identification
novel
ligases
proprietary
ternary
complex
predictive
modeling
capabilities
degradation
tools
cautionary
note
regarding
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
including
without
limitation
implied
express
statements
regarding
strategy
business
plans
focus
plans
timelines
clinical
development
kymera
therapeutics
product
candidates
therapeutic
potential
clinical
benefits
thereof
growth
company
expectations
regarding
future
interactions
food
drug
administration
fda
uses
capital
words
may
might
could
would
expect
plan
anticipate
intend
believe
expect
estimate
seek
predict
future
project
potential
continue
target
similar
words
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
press
release
based
management
current
expectations
beliefs
subject
number
risks
uncertainties
important
factors
may
cause
actual
events
results
differ
materially
expressed
implied
statements
contained
press
release
including
without
limitation
risks
associated
impact
countries
regions
operations
business
well
timing
anticipated
results
current
preclinical
studies
future
clinical
trials
strategy
future
operations
delay
current
preclinical
studies
future
clinical
trials
development
kymera
therapeutics
drug
candidates
risk
results
current
preclinical
studies
may
predictive
future
results
connection
future
clinical
trials
kymera
therapeutics
ability
successfully
demonstrate
safety
efficacy
drug
candidates
timing
outcome
company
planned
interactions
regulatory
authorities
obtaining
maintaining
protecting
intellectual
property
risks
uncertainties
described
greater
detail
section
entitled
risk
factors
final
prospectus
dated
august
filed
pursuant
rule
b
securities
amended
securities
exchange
commission
well
discussions
potential
risks
uncertainties
important
factors
kymera
therapeutics
subsequent
filings
securities
exchange
commission
addition
statements
represent
kymera
therapeutics
views
today
relied
upon
representing
views
subsequent
date
kymera
therapeutics
explicitly
disclaims
obligation
update
statements
representations
warranties
expressed
implied
made
accuracy
statements
contact
investors
bruce
jacobs
chief
financial
officer
christopher
brinzey
westwicke
icr
company
kymera
therapeutics
media
lissette
steele
verge
scientific
communications
kymera
therapeutics
lsteele
